(Q37180860)

18 August 2017

Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment (English)

1 reference

18 August 2017

6

Waldemar Misiorowski

1 reference

18 August 2017

Mimi I Hu

1

1 reference

18 August 2017

Ilya Glezerman

2

1 reference

18 August 2017

Sophie Leboulleux

3

1 reference

18 August 2017

Karl Insogna

4

1 reference

18 August 2017

Rasim Gucalp

5

1 reference

18 August 2017

Bennett Yu

7

1 reference

18 August 2017

Wendy Ying

8

1 reference

18 August 2017

Rajul K Jain

9

1 reference

18 August 2017

language of work or name

English

0 references

publication date

29 August 2013

1 reference

Journal of the National Cancer Institute

18 August 2017

1 reference

18 August 2017

105

1 reference

18 August 2017

18

1 reference

18 August 2017

1417-1420

1 reference

Clinical practice. Hypercalcemia associated with cancer

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Parathyroid hormone-related protein purified from a human lung cancer cell line

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776443

Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23990665

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJT225

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

23990665

1 reference